Page 1,090«..1020..1,0891,0901,0911,092..1,1001,110..»

The race to find a coronavirus treatment: One strategy might be just weeks away, scientists say – USA TODAY

Posted: March 17, 2020 at 6:45 pm

Pressure to create a coronavirus vaccine is increasing by the day, but for a safe vaccine to enter the market, it takes time. USA TODAY

MILWAUKEE In a week whenthe coronavirus closures and quarantines hitlikefalling dominoes the lockdown in Italy,the emptyworkplaces and college campusesin the U.S., suspended sports seasons, canceled festivals far less attention fell on theglobal scientific community's driveto find treatments forthe new virus.

But researchers are already suggesting strategies tohelp patientssuffering from the virus, which is marked by fever, coughing and difficulty breathing. One treatment could be just weeks away.

With no vaccine expected anytime soon, treatmentsarecrucialtosaving the lives of thousands of the infected, especiallyhigh-riskpatients the elderly, those with compromised immune systems and those with chronic illnesses, such as diabetes, heart disease and lung disease.

"I'm very hopeful and very positive. We'll get through this,"said Robert Kruse, a doctor in the Department of Pathology at Johns Hopkins Hospitalin Baltimore. "I've been shocked this week at the measures that have been taken (to alter daily life). They were probably the correct ones, given that they have worked in other countries."

Autoplay

Show Thumbnails

Show Captions

Kruse has been pursuing two treatmentstrategies, one of which has a long history andcould be availablewithinweeks rather than months. The quickest option is likely to be the use ofantibodies from recovered COVID-19 patients. As of Saturday, there were almost 72,000 such patients worldwide. Thevirus has infected about 150,000, killing more than 5,500.

The use of survivor antibodies, serum therapy,dates back to 1891 when it was used successfully to treat a child with diphtheria. Since then, serum from recovered patients has been used "to stem outbreaks of viral diseases such as poliomyelitis, measles, mumps and influenza," according to a paperFriday in The Journal of Clinical Investigation.

"As we are in the midst of a worldwide pandemic, we recommend that institutions consider the emergency use (of serum from recovered patients) and begin preparations as soon as possible. Time is of the essence," wrote the paper's two authors, Arturo Casadevall of Johns Hopkins School of Public Health and Liise-anne Pirofski of the Albert Einstein College of Medicine in New York.

All of the strategies, including the use of serum from recovered patients, have drawbacks. Transfusion of serum carries potential side effects, including fever, allergic reactionsand a very small risk of infectious disease transmission.

Collecting large amounts of serum from recovered patients could be a sizable task. It could turn outthat serum from one recovered patient is enough to save only a singlesick one, explainedKruse at Johns Hopkins. "It's a logistical challenge to put it together, but at the very least there are no hurdles (from the U.S. Food and Drug Administration)to producing the therapy."

Kruse advanced anothertechnique in a paper published in late Januaryin the journal F1000 Research.

His method seeks to take advantage of the new coronavirus' ability to latch onto and enter cells.

Scientists often talk about "cell receptors," which are essentially doors that allow a virus to enter the cell.

The "door" the new coronavirus is entering through is known as the ACE-2 protein. Kruse's technique involves detaching the externalportionof ACE-2, which would act as a decoy for the virus. Thevirus would bind tothe decoy, leaving it unable to reachtheactual door into the cell, and thusunable tocause infection.

"It won't realize, 'Oh gosh, this isn't a cell,'" Kruse explained in an interview. "The virus can't mutate away from this."

Kruse'sdecoy therapy would not be available until fall at the earliest. A similar version of the strategy, however, is being tested now in trials in China.

Afaster optioninvolves what's called "repurposing" a drug.

This is when a drug that has already been found safe and approved fortreatment of one disease also is foundusefulin treating another. One example is thedrug Sildenafil, which is sold as Viagra andused to treat both erectile dysfunction andpulmonary hypertension.

There are three ways in which scientists try to findan existing drug that can treat a new condition.

The rational method involves using drugs that have characteristics and targets that suggestthey might be used to treatthe new condition.

The computational method involves examining protein structures and using them to predict an existing drug that might work.

The final method takes advantage of the vast drug libraries possessed by companies and academic institutions. High-speed technology allows researchers to screen thousands of drugs quickly to determine whether they will act against a specific target.

Considerable hope,interest and money have been invested in one drug not previously approved, remdesivir. The drug was tested against Ebolabut failed in trials.

Gilead Sciences, a biopharmaceutical company based in Foster City, California, announced that two clinical studies of the drugare beginning thismonth. Two more clinical trials of the drug already have begun in China.

In the U.S., the clinical trials process is slow and painstaking, takingseveral years andsometimes much longer.

Another approach to the new virus championed by numerous researchers isthe use oflab-made proteinscalled monoclonal antibodies.

These confer what's called "passive immunity" and have been used beforeto treat cancer, multiple sclerosis,cardiovascular disease and many other conditions.

"The use of monoclonal antibodies is a new era in infectious disease prevention which overcomes many drawbacks associated with serum therapy ... in terms of specificity, purity, low risk of blood-borne pathogen contamination and safety," wrote the authors of a recent paper in the Asian Pacific Journal of Allergy and Immunology.

The biotechnology company Regeneron, based in Tarrytown, New York, started work searching for a monoclonal antibody "for this particular virus in early/mid-January," said Christos Kyratsous, the company's vice president for infectious diseases and viral vector technologies. "But really we started working on it decades ago when we began building our unique end-to-end drug discovery and development technologies."

Gregory Poland, director of Mayo Clinic's Vaccine Research Group, said the use of monoclonal antibodies "needs to be designed and tested in this specific disease, but I wouldn't see any reason it wouldn't work. The idea is right."

Like other scientists, Poland was less hopeful that a vaccine would be developed anytime soon.

"We won't have a vaccine for this outbreak," he said. "It will be before thenext (outbreak)."

Monoclonal antibodies do havepitfalls. They require extensive testing. Also, viruses can mutate and escape from the antibodies. Companies sometimestarget two different parts of the virus to make it harder for the virusto mutate and elude the antibodies.

Ajay K. Sethi,associate professor of population health sciences at the University of Wisconsin-Madison, expressed support for the development of monoclonal antibodies.

"In my opinion, trying a strategy like monoclonal antibodies to provide passive immunity is a good idea," Sethi said.He added that given the technique's past successes, "it is hopeful, but not surprising."

Strategies forcombating the new coronavirus will likely requirereaching patients early before they get too sick. Toward that end, Kruse said he believes the U.S. should pursue the much broader coronavirus testing policythat South Koreaadopted.

"Maybe in the next few weeks we will get to the point where we are testing everyone," he said.

Take a break from coronavirus news: The 12 adorable baby animal photos you need right now

Coronavirus: Here are some TikToks and memes to get you through the panic

Autoplay

Show Thumbnails

Show Captions

Read or Share this story: https://www.usatoday.com/story/news/health/2020/03/15/coronavirus-treatment-could-coming-doctors-say-still-no-vaccine/5052788002/

Excerpt from:
The race to find a coronavirus treatment: One strategy might be just weeks away, scientists say - USA TODAY

Posted in California Stem Cells | Comments Off on The race to find a coronavirus treatment: One strategy might be just weeks away, scientists say – USA TODAY

Single Cell Analysis Market Size Worth $8.02 Billion By 2027 | CAGR: 16.9%: Grand View Research, Inc. – Yahoo Finance

Posted: March 17, 2020 at 6:45 pm

SAN FRANCISCO, March 16, 2020 /PRNewswire/ -- The global single cell analysis marketsize is expected to reach USD 8.02 billion by 2027, registering a CAGR of 16.9% during the forecast period, according to a new report by Grand View Research, Inc. Advancements in molecular techniques which resulted in higher accuracy, ability to perform multiple omics analyses in one cell, and automation, has lowered the barriers for implementation of single-cell analysis techniques across various end-use settings. As a result, companies are investing in introducing novel solutions to accelerate the identification and quantification of genetic information in individual cells for research programs, thereby contributing to revenue growth in this market.

Grand_View_Research_Logo

Key suggestions from the report:

Read 150 page research report with ToC on "Single Cell Analysis Market Size, Share & Trends Analysis Report By Product, By Application (IVF, Cancer, Immunology, Neurology, Stem Cell, Non-invasive Prenatal Diagnosis), By End Use, And Segment Forecasts, 2020 - 2027" at: https://www.grandviewresearch.com/industry-analysis/single-cell-analysis-market

This technology has addressed several research challenges with respect to biological intricacies in stem cell biology, tumor biology, immunology, and other therapeutic areas. This leads to improved therapeutic decision-making with regards to precision medicine, thereby driving the adoption of these assays in personalized therapeutic development.

The growth in research publications depicts the increasing R&D investments. Since R&D activities are considered as the foundation of innovation, investments in R&D activities signify a healthy growth prospect for the single cell analysis market. Moreover, the establishment of new single cell genomics centers in the past years is anticipated to boost the uptake of instruments and consumables for single cell analysis, thus driving the growth.

Grand View Research has segmented the global single cell analysis market on the basis of product, application, end use, and region:

Find more research reports on Biotechnology Industry, by Grand View Research:

Gain access to Grand View Compass, our BI enabled intuitive market research database of 10,000+ reports

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:Sherry JamesCorporate Sales Specialist, USAGrand View Research, Inc.Phone: 1-415-349-0058Toll Free: 1-888-202-9519Email: sales@grandviewresearch.comWeb: https://www.grandviewresearch.comFollow Us: LinkedIn| Twitter

View original content:http://www.prnewswire.com/news-releases/single-cell-analysis-market-size-worth-8-02-billion-by-2027--cagr-16-9-grand-view-research-inc-301024572.html

SOURCE Grand View Research, Inc.

Go here to see the original:
Single Cell Analysis Market Size Worth $8.02 Billion By 2027 | CAGR: 16.9%: Grand View Research, Inc. - Yahoo Finance

Posted in California Stem Cells | Comments Off on Single Cell Analysis Market Size Worth $8.02 Billion By 2027 | CAGR: 16.9%: Grand View Research, Inc. – Yahoo Finance

New Research On Brain Structure Highlights Cells Linked To Alzheimer’s And Autism – BioSpace

Posted: March 17, 2020 at 6:43 pm

New insights into the architecture of the brain have been revealed by scientists at the Wellcome Sanger Institute, the Wellcome-MRC Cambridge Stem Cell Institute and their collaborators. The researchers discovered that cells in the cerebral cortex of mice, called astrocytes, are more diverse than previously thought, with distinct layers of astrocytes across the cerebral cortex that provide the strongest evidence to date of their specialization across the brain.

Published today (16 March) in Nature Neuroscience, the most in-depth study of its kind is set to change the way we think about the brain and the role of cells such as astrocytes. This knowledge will have with implications for the study of neurological disorders, such as Alzheimers, multiple sclerosis and autism.

In the past 20 years, research has shown glial cells to be key players in brain development and function, as well as promising targets for better understanding neurological disorders. Alzheimers causes around two thirds of dementia cases in the UK, which affects around 850,000 individuals at present*. MS is a neurological disorder that affects the central nervous system and impacts around 100,000 people in the UK**. Autism affects around one in every hundred people in the UK***.

Glial comes from the Greek word for glue or putty. At one time, glial cells were thought of as 'brain putty' functionally similar, passive cells whose only function was to fill the space around the all important neurons. However, new studies are showing their critical importance in regulating neuron functions^. Astrocytes are a type of glial cell, so called because of their star-shaped structure^^.

Despite the wealth of knowledge on neuronal function and the organisation of neurons into layers, prior to this study there had been little investigation into whether glial cells across different layers showed different cellular properties. To answer this question, the researchers developed a new methodological approach to provide a more detailed view of the organisation of astrocytes than ever before.

Nucleic acid imaging was carried out on mouse and human brain samples at the University of Cambridge to map how new genes are expressed within tissue. These maps were combined with single cell genomic data at the Wellcome Sanger Institute to extend the molecular description of astrocytes. These data sets were then combined to create a three-dimensional, high-resolution picture of astrocytes in the cerebral cortex.

The team discovered that astrocytes are not uniform as previously thought, but take distinct molecular forms depending on their location in the cerebral cortex. They found that astrocytes are also organised into multiple layers, but that the boundaries of astrocyte layers are not identical to the neuronal layers. Instead, astrocyte layers have less sharply defined edges and overlap the neuronal layers.

Dr Omer Bayraktar, Group Leader at the Wellcome Sanger Institute, said: The discovery that astrocytes are organised into layers that are similar, but not identical to, neuronal layers redefines our view of the structure of the mammalian brain. The structure of the cerebral cortex can no longer simply be seen as the structure of neurons. If you want to properly understand how our brains work, you have to consider how astrocytes are organised and what role they play.

As well as increasing our understanding of brain biology, the findings will have implications for the study and treatment of human neurological disorders. Over the past decade glial cells, rather than neurons, have been heavily implicated in diseases such as Alzheimers and multiple sclerosis.

Professor David Rowitch, senior author of the study and Head of Paediatrics at the University of Cambridge, said: This study shows that the cortical architecture is more complex than previously thought. It provides a basis to begin to understand the precise roles played by astrocytes, and how they are involved in human neurodevelopmental and neurodegenerative diseases.

ENDS

Contact details:Dr Matthew MidgleyPress OfficeWellcome Sanger InstituteCambridge, CB10 1SAPhone: 01223 494856Email: press.office@sanger.ac.uk

Notes to Editors:

In the cerebral cortex of the mammalian brain, neurons are the cells responsible for transmitting information throughout the body. It has long been recognised that the 10-14 billion neurons of the human cerebral cortex are organised into six layers, with distinct populations of neurons in each layer that correspond to their function https://www.dartmouth.edu/~rswenson/NeuroSci/chapter_11.html

* More information on Alzheimers disease can be found here: https://www.alzheimersresearchuk.org/about-dementia/types-of-dementia/alzheimers-disease/about/

**More information about MS can be found here: https://www.mssociety.org.uk/about-ms/what-is-ms

*** More Information on autism is available from the National Autistic Society: https://www.autism.org.uk/about/what-is/asd.aspx

^ An overview of the changing status of glial cells is available at: https://blogs.scientificamerican.com/brainwaves/know-your-neurons-meet-the-glia/

^^ Only half of the cells in the human cerebral cortex are neurons, the other half are glial cells, of which astrocytes are a type. The molecular signals that astrocytes provide are essential for forming synapses between neurons. They regulate synapse formation in the developing brain, as well as refining synapses in the maturing brain 'pruning' extra synapses to sculpt neuronal networks.

Publication:

Omer Ali Bayraktar, Theresa Bartels and Staffan Holmqvist et al. (2020). Astrocyte layers in the mammalian cerebral cortex revealed by a single-cell in situ transcriptomic map. Nature Neuroscience. https://doi.org/10.1038/s41593-020-0602-1

Funding:

The study was supported by the Dr Miriam and Sheldon G. Adelson Medical Research Foundation, National Institute of Health (1R01 MH109912; P01NS08351), NINDS Informatics Center for Neurogenetics and Neurogenomics (P30 NS062691), Wellcome and the European Research Council (281961).

Selected websites:

Wellcome - MRC Cambridge Stem Cell InstituteThe Wellcome - MRC Cambridge Stem Cell Institute is a world-leading centre for stem cell research with a mission to transform human health through a deep understanding of normal and pathological stem cell behaviour. Bringing together biological, clinical and physical scientists operating across a range of tissue types and at multiple scales, we explore the commonalities and differences in stem cell biology in a cohesive and inter-disciplinary manner. In 2019, we relocated to a new purpose-built home on the Cambridge Biomedical Campus. Housing over 350 researchers, including a critical mass of clinician scientists, the Institute integrates with neighbouring disease-focused research institutes and also serves as a hub for the wider stem cell community in Cambridge. https://www.stemcells.cam.ac.uk/

About the University of Cambridge

The mission of the University of Cambridge is to contribute to society through the pursuit of education, learning and research at the highest international levels of excellence. To date, 107 affiliates of the University have won the Nobel Prize.

Founded in 1209, the University comprises 31 autonomous Colleges, which admit undergraduates and provide small-group tuition, and 150 departments, faculties and institutions. Cambridge is a global university. Its 19,000 student body includes 3,700 international students from 120 countries. Cambridge researchers collaborate with colleagues worldwide, and the University has established larger-scale partnerships in Asia, Africa and America.

The University sits at the heart of the Cambridge cluster, which employs 60,000 people and has in excess of 12 billion in turnover generated annually by the 4,700 knowledge-intensive firms in and around the city. The city publishes 341 patents per 100,000 residents. http://www.cam.ac.uk

The Wellcome Sanger InstituteThe Wellcome Sanger Institute is a world leading genomics research centre. We undertake large-scale research that forms the foundations of knowledge in biology and medicine. We are open and collaborative; our data, results, tools and technologies are shared across the globe to advance science. Our ambition is vast we take on projects that are not possible anywhere else. We use the power of genome sequencing to understand and harness the information in DNA. Funded by Wellcome, we have the freedom and support to push the boundaries of genomics. Our findings are used to improve health and to understand life on Earth. Find out more at http://www.sanger.ac.uk or follow us on Twitter, Facebook, LinkedIn and on our Blog.

About WellcomeWellcome exists to improve health by helping great ideas to thrive. We support researchers, we take on big health challenges, we campaign for better science, and we help everyone get involved with science and health research. We are a politically and financially independent foundation. https://wellcome.ac.uk

Visit link:
New Research On Brain Structure Highlights Cells Linked To Alzheimer's And Autism - BioSpace

Posted in Stem Cell Research | Comments Off on New Research On Brain Structure Highlights Cells Linked To Alzheimer’s And Autism – BioSpace

Stem cells: what do bones have to do with boosting immunity? – Health Europa

Posted: March 17, 2020 at 6:43 pm

A research team led by Professor Michael Sieweke, from the Center for Regenerative Therapies TU Dresden (CRTD) and the Center of Immunology of Marseille Luminy (CNRS, INSERM, Aix-Marseille University), has uncovered a surprising property of blood stem cells that contributes to boosting our immunity.

Not only do the stem cells ensure the continuous renewal of blood cells and contribute to the immune response triggered by an infection, but they can also remember previous infectious encounters to drive a more rapid and more efficient immune response in the future.

These cells are found within the soft tissue, or bone marrow, in the centre of large bones such as the hip and thigh bones.

The new findings should have a significant impact on future vaccination strategies and pave the way for new treatments of an underperforming or over-reacting immune system.

Stem cells in our bodies act as reservoirs of cells that divide to produce new stem cells, as well as a myriad of different types of specialised cells that are required to secure tissue renewal and function.

Commonly called blood stem cells, the hematopoietic stem cells (HSC) are found in the bone marrow, the soft tissue that is in the centre of large bones such as the hips or thighs. The role of the cells is to renew the repertoire of blood cells, including cells of the immune system, which are crucial to fight infections and other diseases.

Work from Professor Michael Siewekes laboratory and others over the past years has proven the dogma that HSCs were unspecialised cells, blind to external signals such as infections, was wrong, and has shown that HSCs can actually sense external factors to specifically produce subtypes of immune cells on demand to fight an infection.

Beyond their role in an emergency immune response, the question remained as to the function of HSCs in responding to repeated infectious episodes. The immune system is known to have a memory that allows it to better respond to returning infectious agents. The present study now establishes a central role for blood stem cells in this memory.

Professor Michael Sieweke, Humboldt Professor at TU Dresden, CNRS Research Director and last author of the publication, explained how they found the memory was stored within the cells: The first exposure to LPS causes marks to be deposited on the DNA of the stem cells, right around genes that are important for an immune response. Much like bookmarks, the marks on the DNA ensure that these genes are easily found, accessible and activated for a rapid response if a second infection by a similar agent was to come.

The authors further explored how the memory was inscribed on the DNA, and found C/EBPb to be the major actor, describing a new function for this factor, which is also important for emergency immune responses. Together, these findings should lead to improvements in tuning the immune system or better vaccination strategies.

Sieweke concluded: The ability of the immune system to keep track of previous infections and respond more efficiently the second time they are encountered is the founding principle of vaccines.

Now that we understand how blood stem cells bookmark immune response circuits, we should be able to optimise immunisation strategies to broaden the protection to infectious agents. It could also more generally lead to new ways to boost the immune response when it underperforms or turn it off when it overreacts.

The results of this research are published in Cell Stem Cellon March 12, 2020.

Do you want the latest news and updates from Health Europa? Click here for your free subscription, and stay connected with us here.

Read the original post:
Stem cells: what do bones have to do with boosting immunity? - Health Europa

Posted in Stem Cell Research | Comments Off on Stem cells: what do bones have to do with boosting immunity? – Health Europa

China reports new progress in drug, therapies against Covid-19 – The Star Online

Posted: March 17, 2020 at 6:43 pm

BEIJING: China has completed the clinical research of Favipiravir, an antiviral drug that has shown good clinical efficacy against the Covid-19 (coronavirus) outbreak, according to an official on Tuesday (March 17).

Favipiravir, the influenza drug which was approved for clinical use in Japan in 2014, has shown no obvious adverse reactions in the clinical trial, said Zhang Xinmin, director of the China National Center for Biotechnology Development under the Ministry of Science and Technology, at a press conference.

More than 80 patients have participated in the clinical trial in The Third People's Hospital of Shenzhen, south China's Guangdong Province, including 35 patients taking Favipiravir and 45 patients on a control group.

Results showed that patients receiving Favipiravir treatment turned negative for the virus in a shorter time compared with patients in the control group.

A multi-centred randomised clinical study led by the Zhongnan Hospital of Wuhan University also suggested that the therapeutic effect of Favipiravir is much better than that of the control group.

Favipiravir has been recommended to medical treatment teams and should be included in the diagnosis and treatment plan for Covid-19 as soon as possible, Zhang said.

A Chinese pharmaceutical company has been approved by the National Medical Products Administration to mass-produce the drug and ensure stable supply, Zhang added.

China is also pushing forward the utilization of some advanced technologies such as stem cell and artificial liver and blood purification in the treatment of severe cases.

Zhang said stem cell therapy proves effective in reducing severe inflammatory reactions caused by Covid-19, as well as reducing lung injury and pulmonary fibrosis in patients.

China has initiated several clinical research programs on stem cell therapy against Covid-19, including a stem cell drug that has been approved for clinical trial and a mesenchymal stem cell therapy.

Stem cell therapy has been used to treat 64 patients in severe and critical condition. Those patients' breathing difficulties were gradually relieved and they were generally cured in eight to 10 days.

The therapy also showed advantages in preventing pulmonary fibrosis and improving the long-term prognosis for patients.

The Chinese Society for Cell Biology and the Chinese Medical Association have jointly issued a guideline to standardize the clinical research and application of stem cell therapy against Covid-19.

Zhang said China is trying to use artificial liver and blood purification technology to treat critically ill patients. Patients receiving this treatment have seen reduced levels of inflammatory factors and improvement in chest imaging.

Their time on ventilator support has been decreased by an average of 7.7 days and the required ICU monitoring time has been shortened. - Xinhua/Asian News Network

Visit link:
China reports new progress in drug, therapies against Covid-19 - The Star Online

Posted in Stem Cell Research | Comments Off on China reports new progress in drug, therapies against Covid-19 – The Star Online

Predictive Technology Group Addresses Use of Mesenchymal Stem Cells in Treatment of Secondary Issues Related to Coronavirus – GlobeNewswire

Posted: March 17, 2020 at 6:43 pm

SALT LAKE CITY, March 17, 2020 (GLOBE NEWSWIRE) -- Predictive Technology Group (OTC PINK: PRED) (Predictive or The Company), today announced that last week it began communication with domestic and international agencies and groups to be a supplier ofmesenchymal stem cells (MSCs) for the potential clinical treatmentof patients suffering from secondary issues related to the coronavirus (COVID-19). In other related news today the American Society of Interventional Pain Physicians (ASIPP) issued a statement on COVID-19, discussing practices and urging authorities to approve expanded umbilical cord stem cell infusions as a treatment.WWW.asipp.org/asipp-updates/STATEMENT-FROM-ASIPP-ON-COVID-19

ChinaXiv recently reported (March 2, 2020) the outcomes of seven patients with COVID-19 pneumonia enrolled in a clinical trial at Beijing YouAn Hospital, China. The clinical outcomes, as well as changes in inflammatory and immune function levels, and adverse effects of the enrolled patients were assessed over the 14 days following MSC injection. The patients were treated with MSCs derived from the Whartons jelly layer of the umbilical cord. The pulmonary function and symptoms of all seven patients with COVID-19 pneumonia were significantly improved within 2 days of the MSC transplantation.

Utilizing regenerative medicine technology with the administration of MSCs may help mitigate underlying COVID-19 associated lung damage. While this treatment is not a method to vaccinate nor cure the virus, the results reported in this publication indicate that infected patients may be more likely to combat and survive the related secondary issues of a COVID-19 infection if regenerative technologies are applied.

Given our expertise and proprietary processes for isolating the MSCs from source tissue, combined with our strong safety record in delivering tens of thousands of allografts to the market, it is not surprising that we have received a high number of inquiries regarding our potential involvement with this global health crisis, said Bradley Robinson, CEO of Predictive Technology Group. We are watching the development of clinical trials from around the world and remain poised to help in any we can, pending regulatory guidance. Our experience and capital investments over the past few years has equipped us with the expertise and ability to scale to meet demand, added Robinson.

MSCs have the ability to differentiate into a variety of cell types and are able to resist viral attacks with the expression of interferon gamma stimulated genes (ISGs). With the ability to express ISGs, stem cells would be expected to survive even when transplanted into a patient with an active COVID-19 infection. Stem cells rejuvenate and regenerate cells in the body through various processes involving reduction of inflammation, secretion of substances that protect cells, transfer of mitochondria, reduction of cell death, anti-oxidative effects and improvement of immune system function. These effects are likely to increase survival in patients infected with COVID-19.

Additionally, there is evidence of stem cells aiding in the protection against viral infection. The influenza virus A/H5N1 is known to cause acute lung injury. With the injection of human MSCs, A/H5N1 was reduced in mice and the treatment increased rates of survival (Chan, et al, PNAS 113:3621, 2016).

Umbilical cord tissue is particularly rich in MSCs, which is why many parents choose to store them. As new clinical therapies are discovered, the importance of storing stem cells from perinatal tissue (umbilical cord and placenta) will become a critical source for individuals needing stem cell therapies in the future.

Predictive Technology Group was the first to market and is the current market leader in the United States for the procurement and processing of umbilical cord tissue for clinical use. Predictive has operated its FDA-compliant commercial biologics manufacturing facility for several years. This facility is cGMP and cGTP compliant, ISO13485 certified, and FDA registered. All clinical manufacturing occurs in an ISO 7 certified sterile cleanroom with extensive and advanced testing to assure the absence of contamination.

"We are well positioned to have the procurement, processing and cell culturing expertise and scale to offer stem cell therapy for secondary issues related to COVID-19 infections in both domestic and international markets. While effective vaccines are being developed, US-based stem cell transplants represent a real opportunity to fight the virus and increase survival rates with patients infected worldwide, Bradley Robinson added.

As the major commercial supplier of umbilical cord MSCs in the United States, Predictive is well positioned to continue its leadership role in ensuring a stable supply of this potentially life-saving intervention that has been associated with promoting the regeneration and repair of lung tissue damaged by acute respiratory viral infections, such as those caused by COVID-19. The company plans to evaluate potential research and commercial collaboration opportunities to supply stem cells either directly through Predictive, or in collaboration with other private and/or public entities.

About Predictive Technology Group, Inc.

Predictive Technology Group aims to revolutionize and personalize precision patient care. The Companys entities harness predictive gene-based analytics to develop genetic and molecular diagnostic tests, as well as companion therapeutics, in order to support a patient from diagnosis through treatment. The Companies tests and products empower clinicians to provide their patients with the highest level of care. Predictives subsidiaries include Predictive Laboratories, Predictive Biotech and Predictive Therapeutics.

For more information, visitwww.predtechgroup.com

Forward-Looking Statements:

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

Contacts:

For more information, visit http://www.predtechgroup.comor contact:

Media ContactPatrick BurseyLifeSci Communicationspbursey@lifescicomms.com646-876-4932

Investor ContactJeremy FefferLifeSci Advisorsjeremy@lifesciadvisors.com212-915-2568

View post:
Predictive Technology Group Addresses Use of Mesenchymal Stem Cells in Treatment of Secondary Issues Related to Coronavirus - GlobeNewswire

Posted in Stem Cell Research | Comments Off on Predictive Technology Group Addresses Use of Mesenchymal Stem Cells in Treatment of Secondary Issues Related to Coronavirus – GlobeNewswire

What Jason Hope Says About New Longevity Research – HealthTechZone

Posted: March 17, 2020 at 6:43 pm

Throughout the past decade, various topics related to stem cells have made headlines across all platforms. From being hailed as the most innovative method for eradicating specific diseases, to being protested by various groups and organizations, the use of stem cells has gained national attention repeatedly. With promising initial scientific findings, and avid researchers aiming to solidify the presence of stem cell usage in the realm of science on a normalized basis, increasing numbers of startups, biotech giants, and independent companies are forging ahead with stem cell-related projects. As global connectivity, technological advancements, and the marriage between medicine and technology continues to evolve swiftly, Jason Hope sees stem cells will undoubtedly remaining in the spotlight.

Over 20 years ago, scientists successfully extracted the first human embryonic stem cells, and effectively grew these cells in a lab setting. The remarkable feat of being able to successfully grow the parent cells, which essentially allow for the growth of new cells in the body, was a hopeful moment for the medical sector involved in creating effective regenerative treatments for conditions like heart disease, Alzheimers, stroke, and Parkinsons Disease. Using basic reasoning, the successful regeneration of parent cells could provide the regeneration of undesired cells, leading to anti-aging results, or effective care for many age-related conditions that deteriorate the body over time.

Though this initial breakthrough was promising, the scientific community has not yet made significant strides in bringing stem cell therapy to market in a way that is well-researched, backed by medical associations, and commonly accepted by the scientific community. In fact, the only readily utilized stem cell treatments are related to successfully growing blood cells from matching donors for patients with various blood disorders. According to entrepreneur, philanthropist, and expert in the realm of anti-aging and longevity, Jason Hope, these initial utilization of stem cells are commendable, but require a lot more research in order to maximize the potential widespread benefits of stem cells in medicine.

Hope, who has devoted much of his philanthropic endeavors within the medical industry via groups like the SENS Organization, recognizes that most stem cell implementations are rightfully considered experimental until appropriate research, testing, and development can occur. As an expert in the realm of anti-aging, and the championing of increasing health throughout a lifetime, Jason Hope recognizes the potential distrust that can be formulated by the general public as a result of eager companies making lofty claims or promoting potentially faulty treatments not yet fully vetted by the medical community. Thus, while he remains avidly enthralled by the potential maximization of stem cell therapies, hope supports the long-term research needed to safely, successfully, and effectively generate breakthrough stem cell treatments.

Providing continued backing for the extensive research completed at the SENS (Strategies for Engineered Negligible Senescence) Organization, Hopes contributions aid in the research aiming to create preventative treatments for degenerative diseases and utilizing breakthrough science to increase the overall long-term quality of life for individuals. Instead of focusing on the treatment of symptoms and the disease throughout the progression of the condition, the scientists at SENS work to examine ways to successfully prevent the disease from happening. Through this boundary-pushing work, a lot of their research focuses on stem cell intervention. According to Hope, stem cell treatments for Parkinsons Disease are now in the second stage of clinical trials at SENS. While the process of undergoing such extensive trials may appear slow, it is crucial to maintaining overall public support via successful treatment launches and promising in terms of the long-term possibilities linked to stem cell treatments.

In addition to the research being conducted by SENS, preliminary medical studies are being conducted with a myriad of uses for stem cells. Experimental stem cell transplants of retinal cells were recently utilized in a small research study of macular generation, providing initially promising results for the handful of patients who have received artificially generated retinal cells. Elsewhere, scientists have begun to explore ways to minimize potential rejection of stem cells in organs like the liver, through maximizing the most conducive environment for stem cells to thrive. While these slow-moving vehicles of change are less prominent than startups promising the proverbial Fountain of Youth via experimental stem cell treatments, these medically sound research studies are forming the backbone of stem cell treatment for the future.

As with all scientific and medical innovations, Hope also recognizes the potential risks, hurdles, and roadblocks within the growing field of stem cell research, and integration into medicine. From supply chain concerns to potential long-term side effects, and the risk of overly eager startups making too-lofty claims, Hope understands that the road to the everyday utilization of stem cells remains lengthy and potentially bumpy. However, the proverbial juice may very well be worth the squeeze in this example. As stem cells harvest the potential power to overturn the degenerative effects of some of the most prominent diseases, allow individuals to maintain active health for elongated periods of time, and increase the quality of life for countless individuals, expanding upon the initial promising research is potentially a pivotal point for the medical community and humankind. Though the road to successful scientific integration of stem cells is long, the potential healthcare benefits are limitless, and according to industry experts like Jason Hope, worth investing in, exploring, and championing.

About Jason Hope

An avid entrepreneur, investor, and philanthropist, Jason Hope is a futurist involved in the championing of technological advancement, community involvement, and innovative medical interventions. Deeply passionate about the anti-aging, longevity, and human advancement niche of biomedicine, Hope remains actively involved in various scientific organizations.

After receiving a degree in Finance from ASU, and a subsequent MBA from ASUs W.P. Carey School of Business, Hope developed a successful mobile communications company. Professionally, he currently focuses on investing in startups and developing grant programs for small businesses.

Follow Jason Hope:

LinkedIn | Facebook | Twitter | Medium

Read the rest here:
What Jason Hope Says About New Longevity Research - HealthTechZone

Posted in Stem Cell Research | Comments Off on What Jason Hope Says About New Longevity Research – HealthTechZone

Here’s how to treat coronavirus, according to research – Daily Nation

Posted: March 17, 2020 at 6:43 pm

By XINHUAMore by this Author

China has released the seventh version of the diagnosis and treatment guideline on the novel coronavirus disease (Covid-19).

Here are some drugs and therapies that have been recommended by the guideline, and some medicines that have been found to have the potential to defeat the virus and have entered clinical trials.

Chloroquine Phosphate, a widely used anti-malaria and autoimmune disease drug, has been used for more than 70 years.

The drug has been used in treating 285 critically ill Covid-19 patients in a hospital in Wuhan, and no obvious adverse reactions have been found so far.

In the latest version of the treatment guideline, Chloroquine Phosphate is recommended for Covid-19 patients from 18 to 65.

The amount for patients over 50 kg is 500 mg per dose twice a day for seven days.

The guideline also noted that patients should take less than three antiviral drugs.

Tocilizumab, with the common brand name Actemra, is an injectable synthetic protein that blocks the effects of IL-6 in patients with rheumatoid arthritis.

IL-6 is a protein that the body produces when there is inflammation.The latest version of the guideline suggests the use of Tocilizumab in patients with an increasing level of IL-6 and with extensive lesions in both lungs or severe symptoms.

Chinese researchers have found that a cause of death for severe and critically ill patients infected with the novel coronavirus is cytokine storm, an overreaction of the immune system.

These patients are found with a higher level of IL-6 in their blood.

Last month, the increasing level of IL-6 was recommended as a warning sign that the patient's situation could possibly deteriorate.

Currently, the drug is under clinical trials in 14 hospitals in Wuhan and a total of 272 severe patients had been treated with Tocilizumab as of March 5.

Convalescent plasma, processed from the plasma collected from recovered Covid-19 patients, contains a large number of protective antibodies.

As of February 28, 245 Covid-19 patients have received the therapy and 91 cases have shown improvement in clinical indicators and symptoms.

According to health authorities, plasma therapy has proved safe and effective.

4. TRADITIONAL CHINESE MEDICINE

Traditional Chinese Medicine (TCM) has been proven effective in treating Covid-19 patients.

With TCM treatment, patients with mild symptoms have seen their fever or cough alleviated, according to medical experts.

For severely ill patients, TCM helped relieve symptoms and restore blood oxygen saturation, preventing the patients' conditions from developing into critically ill cases.

TCM decoction Qingfei Paidu Soup has been recommended to medical institutions nationwide on February 6 after data analysis on 214 cases.

As of February 29, the decoction is used in 66 designated hospitals in 10 provincial-level regions in China.

Favipiravir, an influenza drug available on overseas markets, has been put in a parallel controlled study in Shenzhen, Guangdong Province, with 80 patients enlisted.

The initial outcome of the trial shows the drug has relatively obvious efficacy and low adverse reactions.

Experts have suggested expanding the trial to further observe and study its effect.

Remdesivir, developed against Ebola infections by American pharmaceutical company Gilead Sciences, has shown fairly good antiviral activity against the novel coronavirus at the cellular level.

Cao Bin, a respiratory expert who is leading the Remdesivir programme, said on Wednesday that two trials for Remdesivir are going on smoothly and China will share the data with the international community after the programme is completed.

Clinical studies on stem cell therapy, which can inhibit the overreaction of the body's immune system, have also been carried out to treat severe patients.

As of February 21, four patients who have received the therapy have been discharged from hospital, and the trial is expected to be further expanded. Currently, three kinds of stem cells mesenchymal, lung and embryonic stem cells are used in treatments.

Researchers usually inject stem cell products into the lungs.

Meanwhile, the Chinese Academy of Sciences has developed a new stem cell drug, CAStem, which has shown promising results in animal experiments.

The research team has applied for urgent assessment by the National Medical Products Administration.

Approvals by the ethics committee, and clinical observation and evaluation, are in progress.

Several research and trials on applying stem cells to treat Covid-19 patients have been carried out in the country.

See the original post here:
Here's how to treat coronavirus, according to research - Daily Nation

Posted in Stem Cell Research | Comments Off on Here’s how to treat coronavirus, according to research – Daily Nation

GeneDx Celebrates 20 Year History as Pioneer In Genetic Sequencing and Testing – BioBuzz

Posted: March 17, 2020 at 6:42 pm

GeneDx, a global leader in genomics andpatient testing, is celebrating its remarkable 20th anniversary throughout themonth of March.

The Gaithersburg, Maryland company has played an important role in the history of genetic sequencing and the rise of the BioHealth Capital Region as a global biohealth cluster. GeneDx was the very first company to commercially offer NGS (Next Generation Sequencing) testing in a CLIA (Clinical Laboratory Improvement Amendments) lab and has been at the leading edge of genetic sequencing and testing for two decades. The companys whole exome sequencing program and comprehensive testing capabilities are world-renowned.

In its storied 20 yearhistory, GeneDx has provided genetic testing to patients in over 55 countries.The company is known globally as world-class experts in rare and ultra-rarediseases.

In 2000, GeneDx was founded by former National Institutes of Health (NIH) scientists Dr. Sherri Bale and Dr. John Compton. These two genomics experts and thought leaders started GeneDx to complete an important mission: To provide rare and ultra-rare disease patients and families with diagnostic services that were not commercially available at that time.

Prior to launching GeneDx, Bale spent 16 years at NIH, the last nine as Head of the Genetic Studies Section in the Laboratory of Skin Biology. She has been a pioneer during her storied career, publishing over 140 papers, chapters and books in the field. Her 35-year career includes deep experience in clinical, cytogenetic, and molecular genetics research.

Before partnering with Bale to form GeneDx, Compton was an investigator at the Jackson Laboratory, and for the last nine years as a senior scientist in the Genetics Studies Section at the NIH. Comptons work on the molecular genetics of inherited skin disease and expertise in laboratory methodology is known throughout the world. Compton has remarkable experience in the development and application of molecular biological techniques to answer questions about genetics and epidermal differentiation.

GeneDx, like manysuccessful BHCR life science companies, had a humble start, operating initiallyout of the Technology Development Center incubator. Just six years later,GeneDx was acquired by BioreferenceLabs for approximately $17M.

From there, the companylaunched its first array CGH (Comparative Genomic Hybridization) or aCGH testin 2007. An array CGH is also called microarray analysis, which is a atechnique enabling high-resolution, genome-wide screening of segmental genomiccopy number variations (NIH). By 2008, GeneDx had launched its Cardiology NextGeneration Sequencing Panel and by 2011 the company had commercialized itsneurology testing program. In 2012, GeneDx launched its Whole Exome Sequencing (XomeDx) for which it has become so well known in the genomicfield. A year later its Inherited Cancer Panels hit the market. 2018 saw thecompany achieve a significant milestone when it announced ithad performed clinical Exome Sequencing on more than 100,000 individuals.

Both Bale and Comptonhave since retired and GeneDx is currently led by Chief Medical Officer Dr. Gabriele Richard;Chief Innovation Officer Kyle Retterer, MS;Rhonda Brandon, MS

Chief InformationOfficer; and Dr. Sean Hofherr, FACMG, CLIA Laboratory Director & ChiefScientific Officer.

GeneDx has come a longway from its incubator headquarters over the past two decades. With over 450employees, the company continues to deliver on its mission to provide crucialdiagnostic genetic testing capabilities to patients and families across theglobe.

Happy Anniversary GeneDX. Heres to many more.

Over the past 8 years, Chris has grown BioBuzz into a respected brand that is recognized for its community building, networking events and news stories about the local biotech industry. In addition, he runs a Recruiting and Marketing Agency that helps companies attract top talent through a blended model that combines employer branding and marketing services together with a high powered recruiting solution.

See the rest here:
GeneDx Celebrates 20 Year History as Pioneer In Genetic Sequencing and Testing - BioBuzz

Posted in Genetics | Comments Off on GeneDx Celebrates 20 Year History as Pioneer In Genetic Sequencing and Testing – BioBuzz

Race Is Real, But It’s Not Genetic – SAPIENS

Posted: March 17, 2020 at 6:42 pm

Please note that this article includes an image of human remains.

A friend of mine with Central American, Southern European, and West African ancestry is lactose intolerant. Drinking milk products upsets her stomach, and so she avoids them. About a decade ago, because of her low dairy intake, she feared that she might not be getting enough calcium, so she asked her doctor for a bone density test. He responded that she didnt need one because blacks do not get osteoporosis.

My friend is not alone. The view that black people dont need a bone density test is a longstanding and common myth. A 2006 study in North Carolina found that out of 531 African American and Euro-American women screened for bone mineral density, only 15 percent were African American womendespite the fact that African American women made up almost half of that clinical population. A health fair in Albany, New York, in 2000, turned into a ruckus when black women were refused free osteoporosis screening. The situation hasnt changed much in more recent years.

Meanwhile, FRAX, a widely used calculator that estimates ones risk of osteoporotic fractures, is based on bone density combined with age, sex, and, yes, race. Race, even though it is never defined or demarcated, is baked into the fracture risk algorithms.

Lets break down the problem.

First, presumably based on appearances, doctors placed my friend and others into a socially defined race box called black, which is a tenuous way to classify anyone.

Race is a highly flexible way in which societies lump people into groups based on appearance that is assumed to be indicative of deeper biological or cultural connections. As a cultural category, the definitions and descriptions of races vary. Color lines based on skin tone can shift, which makes sense, but the categories are problematic for making any sort of scientific pronouncements.

Second, these medical professionals assumed that there was a firm genetic basis behind this racial classification, which there isnt.

Third, they assumed that this purported racially defined genetic difference would protect these women from osteoporosis and fractures.

The view that black people dont need a bone density test is a longstanding and common myth.

Some studies suggest that African American womenmeaning women whose ancestry ties back to Africamay indeed reach greater bone density than other women, which could be protective against osteoporosis. But that does not mean being blackthat is, possessing an outward appearance that is socially defined as blackprevents someone from getting osteoporosis or bone fractures. Indeed, this same research also reports that African American women are more likely to die after a hip fracture. The link between osteoporosis risk and certain racial populations may be due to lived differences such as nutrition and activity levels, both of which affect bone density.

But more important: Geographic ancestry is not the same thing as race. African ancestry, for instance, does not tidily map onto being black (or vice versa). In fact, a 2016 study found wide variation in osteoporosis risk among women living in different regions within Africa. Their genetic risks have nothing to do with their socially defined race.

When medical professionals or researchers look for a geneticcorrelateto race, they are falling into a trap: They assume thatgeographic ancestry, which does indeed matter to genetics, can be conflated with race, which does not. Sure, different human populations living in distinct places may statistically have different genetic traitssuch as sickle cell trait (discussed below)but such variation is about local populations (people in a specific region), not race.

Like a fish in water, weve all been engulfed by the smog of thinking that race is biologically real. Thus, it is easy to incorrectly conclude that racial differences in health, wealth, and all manner of other outcomes are the inescapable result of genetic differences.

The reality is that socially defined racial groups in the U.S. and most everywhere else do differ in outcomes. But thats not due to genes. Rather, it is due to systemic differences in lived experience and institutional racism.

Communities of color in the United States, for example, often have reduced access to medical care, well-balanced diets, and healthy environments. They are often treated more harshly in their interactions with law enforcement and the legal system. Studies show that they experience greater social stress, including endemic racism, that adversely affects all aspects of health. For example, babies born to African American women are more than twice as likely to die in their first year than babies born to non-Hispanic Euro-American women.

Systemic racism leads to different health outcomes for various populations. The infant mortality rate, for example, for African American infants is double that for European Americans. Kelly Lacy/Pexels

As a professor of biological anthropology, I teach and advise college undergraduates. While my students are aware of inequalities in the life experiences of different socially delineated racial groups, most of them also think that biological races are real things. Indeed, more than half of Americans still believe that their racial identity is determined by information contained in their DNA.

For the longest time, Europeans thought that the sun revolved around the Earth. Their culturally attuned eyes saw this as obvious and unquestionably true. Just as astronomers now know thats not true, nearly all population geneticists know that dividing people into races neither explains nor describes human genetic variation.

Yet this idea of race-as-genetics will not die. For decades, it has been exposed to the sunlight of facts, but, like a vampire, it continues to suck bloodnot only surviving but causing harm in how it can twist science to support racist ideologies. With apologies for the grisly metaphor, it is time to put a wooden stake through the heart of race-as-genetics. Doing so will make for better science and a fairer society.

In 1619, the first people from Africa arrived in Virginia and became integrated into society. Only after African and European bond laborers unified in various rebellions did colony leaders recognize the need to separate laborers. Race divided indentured Irish and other Europeans from enslaved Africans, and reduced opposition by those of European descent to the intolerable conditions of enslavement. What made race different from other prejudices, including ethnocentrism (the idea that a given culture is superior), is that it claimed that differences were natural, unchanging, and God-given. Eventually, race also received the stamp of science.

Swedish taxonomist Carl Linnaeus divided humanity up into racial categories according to his notion of shared essences among populations, a concept researchers now recognize has no scientific basis. Wikimedia Commons

Over the next decades, Euro-American natural scientists debated the details of race, asking questions such as how often the races were created (once, as stated in the Bible, or many separate times), the number of races, and their defining, essential characteristics. But they did not question whether races were natural things. They reified race, making the idea of race real by unquestioning, constant use.

In the 1700s, Carl Linnaeus, the father of modern taxonomy and someone not without ego, liked to imagine himself as organizing what God created. Linnaeus famously classified our own species into races based on reports from explorers and conquerors.

The race categories he created included Americanus, Africanus, and even Monstrosus (for wild and feral individuals and those with birth defects), and their essential defining traits included a biocultural mlange of color, personality, and modes of governance. Linnaeus described Europeaus as white, sanguine, and governed by law, and Asiaticus as yellow, melancholic, and ruled by opinion. These descriptions highlight just how much ideas of race are formulated by social ideas of the time.

In line with early Christian notions, these racial types were arranged in a hierarchy: a great chain of being, from lower forms to higher forms that are closer to God. Europeans occupied the highest rungs, and other races were below, just above apes and monkeys.

So, the first big problems with the idea of race are that members of a racial group do not share essences, Linnaeus idea of some underlying spirit that unified groups, nor are races hierarchically arranged. A related fundamental flaw is that races were seen to be static and unchanging. There is no allowance for a process of change or what we now call evolution.

There have been lots of efforts since Charles Darwins time to fashion the typological and static concept of race into an evolutionary concept. For example, Carleton Coon, a former president of the American Association of Physical Anthropologists, argued in The Origin of Races (1962) that five races evolved separately and became modern humans at different times.

One nontrivial problem with Coons theory, and all attempts to make race into an evolutionary unit, is that there is no evidence. Rather, all the archaeological and genetic data point to abundant flows of individuals, ideas, and genes across continents, with modern humans evolving at the same time, together.

In this map, darker colors correspond to regions in which people tend to have darker skin pigmentation. Reproduced with permission from Dennis ONeil.

A few pundits such as Charles Murray of the American Enterprise Institute and science writers such as Nicholas Wade, formerly of The New York Times, still argue that even though humans dont come in fixed, color-coded races, dividing us into races still does a decent job of describing human genetic variation. Their position is shockingly wrong. Weve known for almost 50 years that race does not describe human genetic variation.

In 1972, Harvard evolutionary biologist Richard Lewontin had the idea to test how much human genetic variation could be attributed to racial groupings. He famously assembled genetic data from around the globe and calculated how much variation was statistically apportioned within versus among races. Lewontin found that only about 6 percent of genetic variation in humans could be statistically attributed to race categorizations. Lewontin showed that the social category of race explains very little of the genetic diversity among us.

Furthermore, recent studies reveal that the variation between any two individuals is very small, on the order of one single nucleotide polymorphism (SNP), or single letter change in our DNA, per 1,000. That means that racial categorization could, at most, relate to 6 percent of the variation found in 1 in 1,000 SNPs. Put simply, race fails to explain much.

In addition, genetic variation can be greater within groups that societies lump together as one race than it is between races. To understand how that can be true, first imagine six individuals: two each from the continents of Africa, Asia, and Europe. Again, all of these individuals will be remarkably the same: On average, only about 1 out of 1,000 of their DNA letters will be different. A study by Ning Yu and colleagues places the overall difference more precisely at 0.88 per 1,000.

The circles in this diagram represent the relative size and overlap in genetic variation in three human populations. The African population circle (blue) is largest because it contains the most genetic diversity. Genetic diversity in European (orange) and Asian (green) populations is a subset of the variation in Africa. Reproduced by permission of the American Anthropological Association.Adapted from the original, which appeared in the book RACE.Not for sale or further reproduction.

The researchers further found that people in Africa had less in common with one another than they did with people in Asia or Europe. Lets repeat that: On average, two individuals in Africa are more genetically dissimilar from each other than either one of them is from an individual in Europe or Asia.

Homo sapiens evolved in Africa; the groups that migrated out likely did not include all of the genetic variation that built up in Africa. Thats an example of what evolutionary biologists call the founder effect, where migrant populations who settle in a new region have less variation than the population where they came from.

Genetic variation across Europe and Asia, and the Americas and Australia, is essentially a subset of the genetic variation in Africa. If genetic variation were a set of Russian nesting dolls, all of the other continental dolls pretty much fit into the African doll.

What all these data show is that the variation that scientistsfrom Linnaeus to Coon to the contemporary osteoporosis researcherthink is race is actually much better explained by a populations location. Genetic variation is highly correlated to geographic distance. Ultimately, the farther apart groups of people are from one another geographically, and, secondly, the longer they have been apart, can together explain groups genetic distinctions from one another. Compared to race, those factors not only better describe human variation, they invoke evolutionary processes to explain variation.

Those osteoporosis doctors might argue that even though socially defined race poorly describes human variation, it still could be a useful classification tool in medicine and other endeavors. When the rubber of actual practice hits the road, is race a useful way to make approximations about human variation?

When Ive lectured at medical schools, my most commonly asked question concerns sickle cell trait. Writer Sherman Alexie, a member of the Spokane-Coeur dAlene tribes, put the question this way in a 1998 interview: If race is not real, explain sickle cell anemia to me.

In sickle cell anemia, red blood cells take on an unusual crescent shape that makes it harder for the cells to pass through small blood vessels. Mark Garlick/Science Photo Library/AP Images

OK! Sickle cell is a genetic trait: It is the result of an SNP that changes the amino acid sequence of hemoglobin, the protein that carries oxygen in red blood cells. When someone carries two copies of the sickle cell variant, they will have the disease. In the United States, sickle cell disease is most prevalent in people who identify as African American, creating the impression that it is a black disease.

Yet scientists have known about the much more complex geographic distribution of sickle cell mutation since the 1950s. It is almost nonexistent in the Americas, most parts of Europe and Asiaand also in large swaths of Northern and Southern Africa. On the other hand, it is common in West-Central Africa and also parts of the Mediterranean, Arabian Peninsula, and India. Globally, it does not correlate with continents or socially defined races.

In one of the most widely cited papers in anthropology, American biological anthropologist Frank Livingstone helped to explain the evolution of sickle cell. He showed that places with a long history of agriculture and endemic malaria have a high prevalence of sickle cell trait (a single copy of the allele). He put this information together with experimental and clinical studies that showed how sickle cell trait helped people resist malaria, and made a compelling case for sickle cell trait being selected for in those areas. Evolution and geography, not race, explain sickle cell anemia.

What about forensic scientists: Are they good at identifying race? In the U.S., forensic anthropologists are typically employed by law enforcement agencies to help identify skeletons, including inferences about sex, age, height, and race. The methodological gold standards for estimating race are algorithms based on a series of skull measurements, such as widest breadth and facial height. Forensic anthropologists assume these algorithms work.

Skull measurements are a longstanding tool in forensic anthropology. Internet Archive Book Images/Flickr

The origin of the claim that forensic scientists are good at ascertaining race comes from a 1962 study of black, white, and Native American skulls, which claimed an 8090 percent success rate. That forensic scientists are good at telling race from a skull is a standard trope of both the scientific literature and popular portrayals. But my analysis of four later tests showed that the correct classification of Native American skulls from other contexts and locations averaged about two incorrect for every correct identification. The results are no better than a random assignment of race.

Thats because humans are not divisible into biological races. On top of that, human variation does not stand still. Race groups are impossible to define in any stable or universal way. It cannot be done based on biologynot by skin color, bone measurements, or genetics. It cannot be done culturally: Race groupings have changed over time and place throughout history.

Science 101: If you cannot define groups consistently, then you cannot make scientific generalizations about them.

Wherever one looks, race-as-genetics is bad science. Moreover, when society continues to chase genetic explanations, it misses the larger societal causes underlying racial inequalities in health, wealth, and opportunity.

To be clear, what I am saying is that human biogenetic variation is real. Lets just continue to study human genetic variation free of the utterly constraining idea of race. When researchers want to discuss genetic ancestry or biological risks experienced by people in certain locations, they can do so without conflating these human groupings with racial categories. Lets be clear that genetic variation is an amazingly complex result of evolution and mustnt ever be reduced to race.

Similarly, race is real, it just isnt genetic. Its a culturally created phenomenon. We ought to know much more about the process of assigning individuals to a race group, including the category white. And we especially need to know more about the effects of living in a racialized world: for example, how a societys categories Race is real, it just isnt genetic. Its a culturally created phenomenon.and prejudices lead to health inequalities. Lets be clear that race is a purely sociopolitical construction with powerful consequences.

It is hard to convince people of the dangers of thinking race is based on genetic differences. Like climate change, the structure of human genetic variation isnt something we can see and touch, so it is hard to comprehend. And our culturally trained eyes play a trick on us by seeming to see race as obviously real. Race-as-genetics is even more deeply ideologically embedded than humanitys reliance on fossil fuels and consumerism. For these reasons, racial ideas will prove hard to shift, but it is possible.

Over 13,000 scientists have come together to formand publicizea consensus statement about the climate crisis, and that has surely moved public opinion to align with science. Geneticists and anthropologists need to do the same for race-as-genetics. The recent American Association of Physical Anthropologists Statement on Race & Racism is a fantastic start.

In the U.S., slavery ended over 150 years ago and the Civil Rights Law of 1964 passed half a century ago, but the ideology of race-as-genetics remains. It is time to throw race-as-genetics on the scrapheap of ideas that are no longer useful.

We can start by getting my friendand anyone else who has been deniedthat long-overdue bone density test.

Here is the original post:
Race Is Real, But It's Not Genetic - SAPIENS

Posted in Genetics | Comments Off on Race Is Real, But It’s Not Genetic – SAPIENS

Page 1,090«..1020..1,0891,0901,0911,092..1,1001,110..»